Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced MelanomaGlobeNewsWire • 10/20/25
Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025GlobeNewsWire • 10/19/25
REPLIMUNE ALERT: Bragar Eagel & Squire, P.C. is Investigating Replimune Group, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmGlobeNewsWire • 10/08/25
REPL Stock Plunges 54% in 3 Months After FDA Rejects Skin Cancer DrugZacks Investment Research • 09/24/25
Investors in Replimune Group, Inc. Should Contact Levi & Korsinsky Before September 22, 2025 to Discuss Your Rights – REPLGlobeNewsWire • 09/22/25
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ReplimuneBusiness Wire • 09/22/25
REPL Deadline: REPL Investors with Losses in Excess of $100K Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit Filed by The Rosen Law FirmPRNewsWire • 09/22/25
Replimune Group, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before September 22, 2025 to Discuss Your Rights - REPLPRNewsWire • 09/22/25
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with the Schall Law FirmPRNewsWire • 09/22/25
REPL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Replimune Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitGlobeNewsWire • 09/21/25
REPL FINAL DEADLINE ALERT: Replimune (REPL) Shares Tank 45% After Company Says No Pathway Identified For Lead Drug RP1, Securities Class Action Pending - Hagens BermanGlobeNewsWire • 09/21/25
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ReplimuneGlobeNewsWire • 09/21/25
REPL DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Replimune Group, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – REPLGlobeNewsWire • 09/21/25
REPL Deadline: Rosen Law Firm Encourages Replimune Group, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important September 22 Deadline in Securities Class Action First Filed by the Firm – REPLBusiness Wire • 09/20/25
Replimune (REPL) Shares Tank 45% After Company Says No Pathway Identified For Lead Drug RP1, Securities Class Action Pending - Hagens BermanPRNewsWire • 09/20/25
Class Action Filed Against Replimune Group, Inc. (REPL) Seeking Recovery for Investors – Contact Levi & KorsinskyGlobeNewsWire • 09/19/25
REPLIMUNE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Replimune Group, Inc. and Encourages Investors to Contact the Firm Before September 22ndGlobeNewsWire • 09/19/25
Shareholders that lost money on Replimune Group, Inc.(REPL) should contact Levi & Korsinsky about pending Class Action - REPLPRNewsWire • 09/19/25
Faruqi & Faruqi Reminds Replimune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 22, 2025 - REPLPRNewsWire • 09/18/25
Shareholders that lost money on Replimune Group, Inc. (REPL) Urged to Join Class Action – Contact The Gross Law Firm to Learn MoreGlobeNewsWire • 09/18/25
Replimune Group, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. September 22, 2025 Deadline to file Lead Plaintiff Motion.GlobeNewsWire • 09/18/25
BREAKING: Replimune Shares Drop Over 40%; Investors Should Contact Block & Leviton By September 22nd To Join Securities Fraud LawsuitGlobeNewsWire • 09/18/25